Health and Human Services Secretary Robert F. Kennedy Jr. declared on Wednesday that he would permit broad patient access to unapproved peptide injections, a class of drugs recently popularized by online influencers. This decision has triggered significant concern among drug safety experts due to its departure from standard regulatory protocols.
The new plan utilizes a mechanism known as "enforcement discretion," which effectively allows companies to produce and distribute these unproven injections without undergoing the usual Food and Drug Administration review process. Consequently, the compounds will bypass critical safeguards, including tests to determine if they are more effective than a placebo or assessments regarding potential risks such as cancer and birth defects.
Secretary Kennedy, who has publicly stated that he has personally benefited from using peptides, had previously hinted at this policy shift on podcasts earlier in the year. However, the official document released Wednesday highlighted the unilateral nature of the action, framing it as a decision made solely by Mr. Kennedy. Notably, FDA scientists had previously advised against widespread use of these peptides, and none were present during at least one meeting held Tuesday to finalize the policy.
The document posted on the H.H.S. website states that the secretary determined the policy advances patient choice and freedom while appropriately protecting safety. Emily Hilliard, a spokeswoman for the Department of Health and Human Services, clarified that the new policy mandates patient-specific prescriptions, traceable ingredients, quality testing, and safety reporting. These measures are intended to hold compounders accountable and provide patients with an alternative to unregulated sellers.
Sources: The New York Times Health.